GluN2A inhibitor - Topia Life Science
Latest Information Update: 23 Dec 2025
At a glance
- Originator Topia Life Sciences
- Class Anxiolytics; Neuropsychotherapeutics; Small molecules
- Mechanism of Action N-methyl D-aspartate receptor subtype 2A antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Anxiety disorders
Most Recent Events
- 22 Dec 2025 GluN2A inhibitor - Topia Life Science is available for licensing as of 22 Dec 2025. https://topialifesciences.com/
- 22 Dec 2025 Topia Life Science plans preclinical trials for Anxiety disorders and Mental disorders (Topia Life Science pipeline; December 2025)
- 19 Dec 2025 Early research in Anxiety disorders in United Kingdom (unspecified route) prior to December 2025 (Topia Life Science pipeline; December 2025)